news
Concanamycin A antibiotic that targets Nef protein could cure HIV
Researchers have revealed that the antibiotic concanamycin A targets a protein called Nef, allowing the immune system to destroy HIV in cells.
List view / Grid view
Protein
article
Bispecific antibodies: the next generation of immuno-oncology drugs
Taylor B Guo, Chief Scientific Officer at I-Mab, describes the potential benefits of bispecific antibodies for cancer therapy and how their dual targeting mechanisms of action may drive their emergence as the next generation of immuno-oncology drugs.
article
Antibody therapeutics for COVID-19
In 2019, the SARS-CoV-2 coronavirus sparked a global pandemic that is likely to continue into 2021. Effective therapeutics that treat the symptoms of the disease and prevent or treat the underlying viral infection are critically required. To meet this need, the global biopharmaceutical industry is evaluating over 50 monoclonal antibody…
article
Assays In-Depth Focus 2020
In this In-Depth Focus find articles exploring the roles of key proteins implicated in Alzheimer's disease and a new technology enabling the identification of novel cancer biomarkers.
article
Targets In-Depth Focus 2020
This in-depth focus includes articles on the importance of a novel target to treat M. tuberculosis infections and how recently identified interactions between the SARS-CoV-2 Spike protein and host epithelial cells could be used in the development of COVID-19 therapeutics.
news
Genetic analysis reveals disease-causing protein drug targets
An analysis of blood protein levels has supported drug target prioritisation by identifying the causal effects of proteins on diseases, a team has shown.
article
Drug Target Review – Issue 3 2020
This issue includes articles that explore how a next-generation genomics platform can be used for COVID-19 research, the elimination of neutralising AAV antibodies for gene therapies and a new quick and cost-effective biomarker technology for cancer diagnostics. Also in this issue are features on antibody therapeutics for COVID-19 and targets…
news
Astrocytes likely contribute to Parkinson’s disease progression
A new study shows astrocytes derived from monogenic Parkinson’s patients have metabolic alterations that mean they could be contributing to disease progression.
article
Innovations for next-generation antibody-drug conjugates
Dr Amrik Basran and Dr Matt Vincent discuss various developments for antibody-drug conjugates to treat cancer.
news
Engineered protein could be used to treat type 2 diabetes
An engineered form of the SMOC1 protein has shown success as a type 2 diabetes treatment in animal models, say researchers.
news
Inhibiting growth factor signalling prevents SARS-CoV-2 replication, report researchers
Scientists have patented their technique of inhibiting cellular growth factor signalling to stop SARS-CoV-2 replication and treat COVID-19.
news
Could STING activation be the target of future cancer immunotherapies?
Researchers demonstrate that their novel small molecule, which activates the STING protein, supresses tumour growth and metastasis in a murine model of aggressive melanoma.
news
Novel alpha-synuclein structures could be the target for future Parkinson’s therapies
Researchers observed new structures of alpha-synuclein aggregates in their study exploring how the presence of cell membrane phospholipids impacts protein aggregation.
news
Novel vaccine protects mice against Staphylococcus aureus infection, say researchers
The novel vaccine 4X-SA-GP harnesses the anti-fungal immune response to provide immunity against Staphylococcus aureus (S. aureus) infection.
news
Researchers observe interaction between antibodies and target proteins
Using cryogenic electron microscopy, scientists have observed the interaction between antibodies and their target molecules, providing information that could be utilised in the development of synthetic antibodies.
